Literature DB >> 25483520

Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.

Cristiano Alicino1, Caterina Merlano, Simona Zappettini, Sergio Schiaffino, Giovanni Della Luna, Cristina Accardo, Roberto Gasparini, Paolo Durando, Giancarlo Icardi.   

Abstract

Post licensure surveillance of adverse events following immunization (AEFI) is a fundamental activity to improve safety and maintain public confidence in vaccines.   Since 2011, the Liguria Region has been involved in the inter-regional project of post-marketing surveillance of AEFI, coordinated by the Italian Medicine Agency and the Veneto region. The main objectives of the project are: (1) to coordinate the surveillance activities in the 8 Italian Regions included in the project; (2) to encourage the signal of AEFI by healthcare workers and patients; (3) to organize education activities addressed to health care workers, and, finally; (4) to establish vaccination counseling services in each Region. In particular, the Ligurian multidisciplinary team, composed by physicians expert in the field of vaccination and pharmacists, is involved in the causality assessment between vaccines and all adverse events signaled within the Liguria Region and in the analysis of all adverse events signaled in Italy as possibly related to influenza vaccines. During 2013, the team has organized 4 courses, addressed to healthcare personnel of vaccination outpatient clinics, focused on European and Italian legislation on pharmaco-vigilance and vaccine-vigilance and aimed at promoting signal of AEFI. Since October 2013, the Liguria Region has been participating to the inter-regional project of active surveillance of adverse events aimed at promoting the signal of AEFI by parents of vaccinated infants. After two years of implementation of the project both the number of reported AEFI and the reporting rate per 100 000 administered doses of vaccine increased. The activities need to be consolidated in the next years in order to guarantee high standard of vaccine safety, maintain the confidence in current immunization programs and reach optimal vaccination coverage rate.

Entities:  

Keywords:  AEFI; Vaccine-vigilance; adverse events following immunization; immunization; safety; surveillance

Mesh:

Substances:

Year:  2014        PMID: 25483520      PMCID: PMC4514437          DOI: 10.4161/hv.34360

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  9 in total

1.  Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Advisory Committee on Causality Assessment.

Authors:  J P Collet; N MacDonald; N Cashman; R Pless
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

2.  Vaccinovigilance in Europe--need for timeliness, standardization and resources.

Authors:  Kari S Lankinen; Satu Pastila; Terhi Kilpi; Hanna Nohynek; P Helena Mäkelä; Patrick Olin
Journal:  Bull World Health Organ       Date:  2004-12-14       Impact factor: 9.408

3.  Vaccine adverse event monitoring systems across the European Union countries: time for unifying efforts.

Authors:  Giovanna Zanoni; Piero Berra; Ilaria Lucchi; Antonio Ferro; Darina O'Flanagan; Daniel Levy-Bruhl; Stefania Salmaso; Giuseppe Tridente
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

4.  Consultancy and surveillance of post-immunisation adverse events in the Veneto region of Italy for 1992-2008.

Authors:  Fabiola Micheletti; Ugo Moretti; Giuseppe Tridente; Giovanna Zanoni
Journal:  Hum Vaccin       Date:  2011-01-01

5.  Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

Authors:  Anita M Loughlin; Colin D Marchant; William Adams; Elizabeth Barnett; Roger Baxter; Steve Black; Christine Casey; Cornelia Dekker; Katherine M Edwards; Jerold Klein; Nicola P Klein; Philip LaRussa; Robert Sparks; Kathleen Jakob
Journal:  Vaccine       Date:  2012-10-09       Impact factor: 3.641

Review 6.  Current status and future directions of post-marketing vaccine safety monitoring with focus on USA and Europe.

Authors:  Jan Bonhoeffer; Steve Black; Hector Izurieta; Patrick Zuber; Miriam Sturkenboom
Journal:  Biologicals       Date:  2012-08-17       Impact factor: 1.856

7.  Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria.

Authors:  Hazel J Clothier; Nigel W Crawford; Ann Kempe; Jim P Buttery
Journal:  Commun Dis Intell Q Rep       Date:  2011-12

8.  Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine.

Authors:  Cristiano Alicino; Maria Teresa Infante; Ilaria Gandoglia; Nadia Miolo; Gian Luigi Mancardi; Simona Zappettini; Elisabetta Capello; Andrea Orsi; Tiziano Tamburini; Marina Grandis
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Global immunization: status, progress, challenges and future.

Authors:  Philippe Duclos; Jean-Marie Okwo-Bele; Marta Gacic-Dobo; Thomas Cherian
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14
  9 in total
  12 in total

1.  Safety profile of the meningococcal conjugate vaccine (Menafrivac™) in clinical trials and vaccination campaigns: a review of published studies.

Authors:  Jerome Ateudjieu; Beat Stoll; Anne Cecile Bisseck; Ayok M Tembei; Blaise Genton
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

2.  Lactoferrin acts as an adjuvant during influenza vaccination of neonatal mice.

Authors:  Michael P Sherman; Curtis J Pritzl; Chuan Xia; Mindy M Miller; Habib Zaghouani; Bumsuk Hahm
Journal:  Biochem Biophys Res Commun       Date:  2015-10-22       Impact factor: 3.575

Review 3.  Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes.

Authors:  Bradford S Powell; Alexander K Andrianov; Peter C Fusco
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

4.  Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season.

Authors:  Anne Laure Chabanon; Hélène Bricout; Céline Ballandras; Audrey Souverain; Timothy David Caroe; Karina M Butler
Journal:  Hum Vaccin Immunother       Date:  2017-12-20       Impact factor: 3.452

5.  Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.

Authors:  Sonja Gandhi-Banga; Anne-Laure Chabanon; Cecile Eymin; Timothy Caroe; Karina Butler; Annick Moureau
Journal:  Hum Vaccin Immunother       Date:  2019-03-27       Impact factor: 3.452

6.  Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data.

Authors:  Meredith Woodward; Ann Marko; Susan Galea; Barry Eagel; Walter Straus
Journal:  Open Forum Infect Dis       Date:  2019-08-01       Impact factor: 3.835

7.  Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017.

Authors:  F Moretti; L Gonella; S Gironi; A R Marra; C Santuccio; P Felicetti; F Petronzelli; P Marchione; S A Barnaba; A Poli; G Zanoni; U Moretti
Journal:  Sci Rep       Date:  2020-08-24       Impact factor: 4.379

8.  Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017.

Authors:  Pasquale Stefanizzi; Sara De Nitto; Francesco Patano; Francesco Paolo Bianchi; Davide Ferorelli; Paolo Stella; Domenica Ancona; Vito Bavaro; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2020-02-10       Impact factor: 3.452

Review 9.  Safety of Co-Administration Versus Separate Administration of the Same Vaccines in Children: A Systematic Literature Review.

Authors:  Jorgen Bauwens; Luis-Henri Saenz; Annina Reusser; Nino Künzli; Jan Bonhoeffer
Journal:  Vaccines (Basel)       Date:  2019-12-31

10.  Enhanced passive safety surveillance of a trivalent and a quadrivalent influenza vaccine in Denmark and Finland during the 2018/2019 season.

Authors:  Laurence Serradell; Sophie Wagué; Annick Moureau; Markku Nissilä; Anne-Laure Chabanon
Journal:  Hum Vaccin Immunother       Date:  2020-09-23       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.